PMID- 36568262
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230103
IS  - 2590-2571 (Electronic)
IS  - 2590-2571 (Linking)
VI  - 3
DP  - 2022
TI  - miRNA nanoencapsulation to regulate the programming of the blood-brain barrier 
      permeability by hypoxia.
PG  - 100129
LID - 10.1016/j.crphar.2022.100129 [doi]
LID - 100129
AB  - Central nervous system (CNS)-related diseases are difficult to treat as most 
      therapeutic agents they cannot reach the brain tissue, mainly due to the 
      blood-brain barrier (BBB), arguably the tightest barrier between the human body 
      and cerebral parenchyma, which routinely excludes most xenobiotic therapeutics 
      compounds. The BBB is a multicellular complex that structurally forms the 
      neurovascular unit (NVU) and is organized by neuro-endothelial and glial cells. 
      BBB breakdown and dysfunction from the cerebrovascular cells lead to leakages of 
      systemic components from the blood into the CNS, contributing to neurological 
      deficits. Understanding the molecular mechanisms that regulate BBB permeability 
      and disruption is essential for establishing future therapeutic strategies to 
      restore permeability and improve cerebrovascular health. MicroRNAs (miRNAs), a 
      type of small non-coding RNAs, are emerging as an important regulator of BBB 
      integrity by modulating gene expression by targeting mRNA transcripts. miRNAs is 
      implicated in the development and progression of various illnesses. Conversely, 
      nanoparticle carriers offer unprecedented opportunities for cell-specific 
      controlled delivery of miRNAs for therapeutic purposes. In this sense, we present 
      in this graphical review critical evidence in the regulation of cell junction 
      expression mediated by miRNAs induced by hypoxia and for the use of nanoparticles 
      for the delivery of miRNA-based therapeutics in the treatment of BBB 
      permeability.
CI  - (c) 2022 The Authors.
FAU - Figueroa, Esteban G
AU  - Figueroa EG
AD  - Laboratory of Fetal Neuroprogramming, Institute of Health Sciences, Universidad 
      de O'Higgins, Rancagua, Chile.
FAU - Caballero-Roman, Aitor
AU  - Caballero-Roman A
AD  - Pharmacy and Pharmaceutical Technology, and Physical Chemistry Department, 
      Faculty of Pharmacy and Food Sciences, University of Barcelona, Avinguda Joan 
      XXIII, 27-31, 08028, Barcelona, Spain.
FAU - Tico, Josep R
AU  - Tico JR
AD  - Pharmacy and Pharmaceutical Technology, and Physical Chemistry Department, 
      Faculty of Pharmacy and Food Sciences, University of Barcelona, Avinguda Joan 
      XXIII, 27-31, 08028, Barcelona, Spain.
FAU - Minarro, Montserrat
AU  - Minarro M
AD  - Pharmacy and Pharmaceutical Technology, and Physical Chemistry Department, 
      Faculty of Pharmacy and Food Sciences, University of Barcelona, Avinguda Joan 
      XXIII, 27-31, 08028, Barcelona, Spain.
FAU - Nardi-Ricart, Anna
AU  - Nardi-Ricart A
AD  - Pharmacy and Pharmaceutical Technology, and Physical Chemistry Department, 
      Faculty of Pharmacy and Food Sciences, University of Barcelona, Avinguda Joan 
      XXIII, 27-31, 08028, Barcelona, Spain.
FAU - Gonzalez-Candia, Alejandro
AU  - Gonzalez-Candia A
AD  - Laboratory of Fetal Neuroprogramming, Institute of Health Sciences, Universidad 
      de O'Higgins, Rancagua, Chile.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20220915
PL  - Netherlands
TA  - Curr Res Pharmacol Drug Discov
JT  - Current research in pharmacology and drug discovery
JID - 9918300982506676
PMC - PMC9780061
OTO - NOTNLM
OT  - Epigenetic
OT  - Hypoxia
OT  - Nanoparticle
OT  - Nose-to-brain
OT  - miRNA
COIS- The authors declare the following financial interests/personal relationships 
      which may be considered as potential competing interests:Alejandro 
      Gonzalez-Candia reports article publishing charges was provided by University of 
      O'Higgins. Alejandro Gonzalez-Candia reports a relationship with University of 
      O'Higgins that includes: employment.
EDAT- 2022/12/27 06:00
MHDA- 2022/12/27 06:01
PMCR- 2022/09/15
CRDT- 2022/12/26 03:48
PHST- 2022/07/20 00:00 [received]
PHST- 2022/09/11 00:00 [accepted]
PHST- 2022/12/26 03:48 [entrez]
PHST- 2022/12/27 06:00 [pubmed]
PHST- 2022/12/27 06:01 [medline]
PHST- 2022/09/15 00:00 [pmc-release]
AID - S2590-2571(22)00049-9 [pii]
AID - 100129 [pii]
AID - 10.1016/j.crphar.2022.100129 [doi]
PST - epublish
SO  - Curr Res Pharmacol Drug Discov. 2022 Sep 15;3:100129. doi: 
      10.1016/j.crphar.2022.100129. eCollection 2022.